BNP Paribas Asset Management
BCRX icon

BNP Paribas Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

BNP Paribas Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6K Buy
2,955
+72
+2% +$651 ﹤0.01% 1947
2026
Q1 		$27.4K Buy
2,883
+715
+33% +$5.55K ﹤0.01% 1927
2025
Q4 		$17K Buy
2,168
+504
+30% +$3.64K ﹤0.01% 1997
2025
Q3 		$13K Hold
1,664
– – ﹤0.01% 1541
2025
Q2 		$15K Buy
+1,664
New +$15.5K ﹤0.01% 1611
2023
Q4 		– Sell
-2,390,948
Closed -$16.9M – 849
2023
Q3 		$16.9M Sell
2,390,948
-19,242
-0.8% -$138K 0.05% 315
2023
Q2 		$17M Sell
2,410,190
-477,549
-17% -$3.83M 0.05% 306
2023
Q1 		$24.1M Buy
2,887,739
+25,352
+0.9% +$244K 0.08% 255
2022
Q4 		$32.9M Buy
2,862,387
+581,434
+25% +$7.25M 0.12% 207
2022
Q3 		$28.7M Buy
2,280,953
+181,626
+9% +$2.34M 0.11% 213
2022
Q2 		$22.2M Buy
2,099,327
+434,071
+26% +$4.48M 0.08% 262
2022
Q1 		$27.1M Sell
1,665,256
-225,904
-12% -$3.62M 0.09% 252
2021
Q4 		$26.2M Buy
+1,891,160
New +$25M 0.09% 267
2015
Q1 		– Sell
-16,328
Closed -$199K – 1051
2014
Q4 		$199K Buy
+16,328
New +$180K ﹤0.01% 949

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BNP Paribas Asset Management's BCRX Position: Q2 2026 in Review

BNP Paribas Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 2.5% in Q2 2026, buying an estimated $651 and bringing the position to 2,955 shares worth $29.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

BNP Paribas Asset Management first reported a position in BCRX in Q4 2014 and has held it in 14 quarters since. The position peaked at $32.9M in Q4 2022. 225 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • BNP Paribas Asset Management held 2,955 shares of BioCryst Pharmaceuticals worth $29.6K as of Q2 2026.
  • BNP Paribas Asset Management bought 72 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $651.
  • BioCryst Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1947 holding.
  • BNP Paribas Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 14 quarters since.
  • BNP Paribas Asset Management's BioCryst Pharmaceuticals position peaked at $32.9M in Q4 2022.
  • 225 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.